StreetInsider.com News Articles

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 29 May 2026 16:01:00 -0400

VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to 10 new non-officer employees consisting of an aggregate of 32,750 share options and 19,200 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of May 28, 2026 and were granted as inducements material to the

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 29 May 2026 16:01:00 -0400

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 29 May 2026 16:01:00 -0400

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 29 May 2026 16:01:00 -0400

Xenon Pharmaceuticals (XENE) PT Raised to $82 at JPMorgan

Wed, 27 May 2026 07:58:36 -0400

JPMorgan analyst Tessa Romero raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $82.00 (from $80.00) while maintaining a Overweight rating.

Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: JANUS HENDERSON GROUP PLC

Fri, 15 May 2026 11:23:00 -0400

si-local-file:///var/storage/secattach/20260515/26502132.html

Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: JANUS HENDERSON GROUP PLC

Fri, 15 May 2026 11:23:00 -0400

si-local-file:///var/storage/secattach/20260515/26502132.html

Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: Avoro Capital Advisors LLC

Fri, 15 May 2026 08:17:00 -0400

si-local-file:///var/storage/secattach/20260515/26499954.html

Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: Avoro Capital Advisors LLC

Fri, 15 May 2026 08:17:00 -0400

si-local-file:///var/storage/secattach/20260515/26499954.html

Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC

Fri, 15 May 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260515/26499270.html

Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: DRIEHAUS CAPITAL MANAGEMENT LLC

Fri, 15 May 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260515/26499270.html

Form 4 Xenon Pharmaceuticals For: May 12 Filed by: GANNON STEVEN

Wed, 13 May 2026 21:41:00 -0400

si-local-file:///var/storage/secattach/20260513/26488179.html

Form 4 Xenon Pharmaceuticals For: May 12 Filed by: GANNON STEVEN

Wed, 13 May 2026 21:41:00 -0400

si-local-file:///var/storage/secattach/20260513/26488179.html

Xenon Pharmaceuticals (XENE) PT Raised to $80 at JPMorgan

Tue, 12 May 2026 08:08:04 -0400

JPMorgan analyst Tessa Romero raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $80.00 (from $77.00) while maintaining a Overweight rating.

Xenon Pharmaceuticals (XENE) PT Raised to $82 at RBC Capital

Fri, 08 May 2026 07:41:44 -0400

RBC Capital analyst Brian Abrahams raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $82.00 (from $80.00) while maintaining a Outperform rating.

Xenon Pharmaceuticals (XENE) PT Lowered to $78 at Needham

Fri, 08 May 2026 07:29:18 -0400

Needham analyst Serge Belanger lowered the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $78.00 (from $80.00) while maintaining a Buy rating.

Xenon Pharmaceuticals (XENE) Tops Q1 EPS by 1c

Thu, 07 May 2026 17:47:38 -0400

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q1 EPS of ($1.17), $0.01 better than the analyst estimate of ($1.18).

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

Form 10-Q Xenon Pharmaceuticals For: Mar 31

Thu, 07 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260507/26454418.html

Form 10-Q Xenon Pharmaceuticals For: Mar 31

Thu, 07 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260507/26454418.html

Form 8-K Xenon Pharmaceuticals For: May 07

Thu, 07 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260507/26452724.html

Form 8-K Xenon Pharmaceuticals For: May 07

Thu, 07 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260507/26452724.html

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 16:01:00 -0400

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026
Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and depression indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027
Phase 1 studies of novel Na_V1.7 (XEN1701) and K_V7 (XEN1120) candidates expected to complete H2 2026 to support Phase 2 proof-of-concept studies in pain
Cash, cash equivalents and marketable securities of $1.3 billion extends cash runway into 2029
Conference call at 4:30 pm ET today

VANCOUVER,

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 16:01:00 -0400

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026
Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and depression indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027
Phase 1 studies of novel Na_V1.7 (XEN1701) and K_V7 (XEN1120) candidates expected to complete H2 2026 to support Phase 2 proof-of-concept studies in pain
Cash, cash equivalents and marketable securities of $1.3 billion extends cash runway into 2029
Conference call at 4:30 pm ET today

VANCOUVER,

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 16:01:00 -0400

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026
Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and depression indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027
Phase 1 studies of novel Na_V1.7 (XEN1701) and K_V7 (XEN1120) candidates expected to complete H2 2026 to support Phase 2 proof-of-concept studies in pain
Cash, cash equivalents and marketable securities of $1.3 billion extends cash runway into 2029
Conference call at 4:30 pm ET today

VANCOUVER,

Xenon Reports Q1 2026 Financial Results and Provides Business Update

Thu, 07 May 2026 16:01:00 -0400

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026
Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and depression indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027
Phase 1 studies of novel Na_V1.7 (XEN1701) and K_V7 (XEN1120) candidates expected to complete H2 2026 to support Phase 2 proof-of-concept studies in pain
Cash, cash equivalents and marketable securities of $1.3 billion extends cash runway into 2029
Conference call at 4:30 pm ET today

VANCOUVER,